Back to Search Start Over

β-Glucan exacerbates allergic asthma independent of fungal sensitization and promotes steroid-resistant T H 2/T H 17 responses.

Authors :
Zhang Z
Biagini Myers JM
Brandt EB
Ryan PH
Lindsey M
Mintz-Cole RA
Reponen T
Vesper SJ
Forde F
Ruff B
Bass SA
LeMasters GK
Bernstein DI
Lockey J
Budelsky AL
Khurana Hershey GK
Source :
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2017 Jan; Vol. 139 (1), pp. 54-65.e8. Date of Electronic Publication: 2016 Apr 20.
Publication Year :
2017

Abstract

Background: Allergic sensitization to fungi has been associated with asthma severity. As a result, it has been largely assumed that the contribution of fungi to allergic disease is mediated through their potent antigenicity.<br />Objective: We sought to determine the mechanism by which fungi affect asthma development and severity.<br />Methods: We integrated epidemiologic and experimental asthma models to explore the effect of fungal exposure on asthma development and severity.<br />Results: We report that fungal exposure enhances allergen-driven T <subscript>H</subscript> 2 responses, promoting severe allergic asthma. This effect is independent of fungal sensitization and can be reconstituted with β-glucan and abrogated by neutralization of IL-17A. Furthermore, this severe asthma is resistant to steroids and characterized by mixed T <subscript>H</subscript> 2 and T <subscript>H</subscript> 17 responses, including IL-13 <superscript>+</superscript> IL-17 <superscript>+</superscript> CD4 <superscript>+</superscript> double-producing effector T cells. Steroid resistance is dependent on fungus-induced T <subscript>H</subscript> 17 responses because steroid sensitivity was restored in IL-17rc <superscript>-/-</superscript> mice. Similarly, in children with asthma, fungal exposure was associated with increased serum IL-17A levels and asthma severity.<br />Conclusion: Our data demonstrate that fungi are potent immunomodulators and have powerful effects on asthma independent of their potential to act as antigens. Furthermore, our results provide a strong rationale for combination treatment strategies targeting IL-17A for this subgroup of fungus-exposed patients with difficult-to-treat asthma.<br />Competing Interests: The authors have declared that no conflict of interest exists. AL Budelsky is a paid employee and stockholder in Amgen, Inc.<br /> (Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-6825
Volume :
139
Issue :
1
Database :
MEDLINE
Journal :
The Journal of allergy and clinical immunology
Publication Type :
Academic Journal
Accession number :
27221135
Full Text :
https://doi.org/10.1016/j.jaci.2016.02.031